Precision Radiation Oncology · Published 2025-12-01 · DOI 10.1002/pro6.70038
Abstract Sinonasal teratocarcinosarcoma (SNTCS) is a rare and aggressive malignant tumor that is difficult to diagnose and lacks a standard therapeutic strategies. Here, we report a case of SNTCS harboring a SMARCA4 deletion and a CTNNB1 mutation. Following incomplete surgical resection, the patient received synchronous postoperative chemotherapy with tomotherapy (TOMO) radiation and achieved a complete response lasting for > 47 months with tolerated side effects. This case suggests that SMARCA4 deletion and CTNNB1 mutation may be key molecular events in the development of SNTCS, potentially providing valuable clues for its diagnosis. Moreover, to the best of our knowledge, this is the first case demonstrating that TOMO technology can be a beneficial option for SNTCS radiotherapy.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →